Pfizer sees emergency use filing for COVID-19 vaccine after U.S. election By Reuters

Pfizer sees emergency use filing for COVID-19 vaccine after U.S.


© Reuters. Logo of U.S. pharmaceutical corporation Pfizer Inc. is seen in Zurich

By Manas Mishra

(Reuters) – Pfizer Inc (N:) said on Friday it may file for authorization of the COVID-19 vaccine it is developing with German partner BioNTech (F:) in late November, making it unlikely a vaccine will be available before U.S. elections as President Donald Trump has promised.

The regulatory filing for the vaccine could come as soon as safety data is available, possibly in the third week of November, Pfizer said, lifting the company’s shares and the broader U.S. stock market.

The timeline now allows for a possible U.S. authorization of a coronavirus vaccine this year, a key step in controlling the COVID-19 pandemic, which has killed more than a million people and ravaged the global economy.

The U.S. Food and Drug Administration said earlier this month it wants at least two months of safety data on half of the trial participants before authorizing emergency use of any experimental coronavirus vaccine.

While the White House cleared the guidance, Trump has called the new rules a ‘political hit job’ as they undercut hopes of getting a vaccine before voters go to polls on Nov. 3.

Based on current trial enrollment and dosing in a late-stage trial, Pfizer expects to have that safety data in the third week of November, Chief Executive Officer Albert Bourla said in an open letter posted on the company’s website.

Bourla noted in the letter that the filing depended on several other factors, including initial data on effectiveness that may or may not be available by late October.

He said the company plans to share efficacy data with the public as soon as practical. (https://

Pfizer’s shares rose 2.4% in premarket trading, while BioNTech’s U.S-listed shares were up 3.3% before the opening bell.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *


About us

InvestLab is a financial services technology company focused on the global trading market. Founded in 2010 in Hong Kong, the company develops trading, market data, and social research products that enable individual investors and small to mid-size brokers to access global markets. We provide brokers and financial institutions cross border capabilities for retail investors into 43 markets globally.


CONTACT US

CALL US ANYTIME